PersonGen BioTherapeutics
PrivateLast Round
Series B
Jan 1, 2022
Total Funding Raised
$51.6M
Company Overview
PersonGen BioTherapeutics operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series B round in January 2022.
PersonGen BioTherapeutics is a biotechnology company that develops innovative cellular immunotherapies, including CAR-T cell therapies, for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PersonGen BioTherapeutics Comparables
Compare PersonGen BioTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hebei Senlang Biotechnology Co., Ltd. | 88% | |
| Wuhan Bio-Raid Biotechnology | 87% | |
| Juventas Cell Therapy Ltd. | 86% |
For institutional investors. Book with your work email.
PersonGen BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 1, 2022 | ||||
| Series A | May 1, 2021 | ||||
| Strategic | Nov 11, 2015 | ||||
| Angel | Aug 1, 2012 |
For institutional investors. Book with your work email.
PersonGen BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Shenzhen Sangel Venture Capital | Series A |
| YuanBio Venture Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 4, 2025
Monthly visitors grew 2789% MoM to 1.3K.
- Jan 1, 2022
$31M round led by Nanjing Huatai Guoxin and China Kim Kaide.
For institutional investors. Book with your work email.
PersonGen BioTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PersonGen BioTherapeutics's valuation, stock price, and market status.
Is PersonGen BioTherapeutics a public or private company?
PersonGen BioTherapeutics is a private company.
What is the current stock price of PersonGen BioTherapeutics?
PersonGen BioTherapeutics is a private company, so its shares have no public market price. Caplight tracks PersonGen BioTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PersonGen BioTherapeutics worth (valuation)?
Valuation information for PersonGen BioTherapeutics is not publicly available.
Can I buy PersonGen BioTherapeutics stock?
PersonGen BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PersonGen BioTherapeutics's last funding round?
PersonGen BioTherapeutics's most recent funding round was Series B on January 1, 2022.
Who are the main investors in PersonGen BioTherapeutics?
Key investors in PersonGen BioTherapeutics include YuanBio Venture Capital.
Will PersonGen BioTherapeutics IPO soon?
No public IPO plans have been announced for PersonGen BioTherapeutics.
How can I track PersonGen BioTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in PersonGen BioTherapeutics's shares on secondary markets.